Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2003-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill
them or deliver tumor-killing substances to them without harming normal cells. Drugs used in
chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
die. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of trastuzumab plus docetaxel in treating
women who have recurrent or metastatic breast cancer.